+++ Ihre Meinung ist uns wichtig: Wie zufrieden sind Sie mit finanzen.ch? - Hier an unserer Umfrage teilnehmen! +++ -w-
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
06.03.2019 15:12:11

Alnylam Pharmaceuticals stock down 7.5% after announcing results of Phase 3 givosiran trial

Shares of Alnylam Pharmaceuticals Inc. fell 7.5% in premarket trade Wednesday after the company announced results of a Phase 3 study of givosiran, an RNA interference therapy for the treatment of acute hepatic porphyria, a family of rare genetic diseases that can cause potentially life-threatening attacks of severe abdominal pain, weakness and fatigue. The study met its primary endpoint -- reducing the yearly rate of porphyria attacks compared with placebo -- and hit five of nine secondary endpoints. But investors seemed spooked by the high percentage of serious adverse events reported by patients on givosiran compared with those on a placebo: 20.8% of those on givosiran reported serious adverse events compared to 8.7% of patients on placebo, though the difference in overall adverse events was not as stark, with 89.6% of patients on the drug reporting adverse events of any kind compared with 80.4% of patients on placebo. One patient discontinued treatment after seeing the amount of the liver enzyme alanine aminotransferase increase to more than eight times the normal number. Acute hepatic porphyria happens when a genetic defect leads to issues with one of the enzymes responsible for making heme in the liver. That causes a build-up of heme precursors, which are toxic to the body. Alnylam's givosiran targets an enzyme in the heme-making pathway called aminolevulinic acid synthase 1 (ALAS1). Alnylam said full study results will be presented in April and the company plans to submit a new drug application in mid-2019. Shares of Alnylam have gained 10.8% in the past 3 months, while the S&P 500 has gained 3.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Weiter zum vollständigen Artikel bei "Market Watch"

Analysen zu Alnylam Pharmaceuticals Inc.mehr Analysen

01.10.18 Alnylam Pharmaceuticals Overweight Cantor Fitzgerald
13.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
07.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
05.07.18 Alnylam Pharmaceuticals Buy Chardan Capital Markets
04.05.18 Alnylam Pharmaceuticals Hold Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

Spannung vor Handelsgesprächen steigt | BX Swiss TV

Aktien in diesem Artikel

Finanzen.net News